“Considered by peers as ‘one of
the best generic Hatch-Waxman
litigation firms on the east coast.’”
– LMG Life Sciences
Visit our new blog at www.biosimilarsip.com
“Rothwell Figg is known for ‘meticulous patent drafting.’ Solely based in the capital, [Rothwell Figg] knows all the ins and outs of the D.C. scene and the USPTO.”
Post-Grant Trial Practice
“[This] compact yet heavy-hitting IP boutique has a client list that is the envy of many. Marquee names are drawn here for several compelling reasons: a persuasive win rate in high-stakes cases, the advanced technical backgrounds of its litigators, great comparative value and renowned expertise in post-grant procedures.”
Visit our new blog at www.ptablaw.com
Represented Mylan Pharmaceutical in an infringement claim made by Bristol-Myers Squibb related to the drug Buspar (buspirone).
Bristol-Myers motioned to dismiss antitrust counterclaims made by Mylan. The Court ruled a summary judgment of noninfringement. The court also denied Bristol’s motion and suing Mylan on it, as well as held that Bristol had acted in an objectively unreasonable fashion in listing the metabolite patent for buspirone in the Orange Book.
Bristol-Myers settled the antitrust claims by paying $535 million, including $35 million to Mylan after an initial ruling in favor of Mylan, 29 State Attorneys General, and several plaintiff class action groups who had joined Mylan’s suit.
company’s IP case
Patent troll CyberFone Systems LLC alleges Warner Bros. Entertainment Inc., CBS Interactive Inc., and dozens of other companies infringed a patent which covers a system of entering transaction data into databases because it covers an abstract concept rather than a specific invention.
The district court granted defendants motion for summary judgment that CyberFone’s patent was invalid under USC 101. Rothwell Figg took the lead in drafting and arguing the motion on behalf of the defendants. Rothwell Figg also took the lead in drafting and arguing against CyberFone’s appeal to the Federal Circuit.
February 2014, the three-judge Federal Circuit panel upheld the District of Delaware’s ruling that invalidated a software patent that CyberFone Systems LLC; alleged the 81 companies including CBS, CNN and Fox News infringed because it was not patent eligible under 35 USC 101.
Shaping a 360°
defense for leading
360° IP Performance
Rothwell Figg is a multifaceted intellectual property firm for high-stakes legal matters.
- Rothwell Figg Attorneys Honored to be Named Among the World’s Leading Patent Professionals
Six Rothwell Figg partners are honored to be recognized in IAM Patent 1000 – The World’s Leading Patent Professionals 2017, a guide that identifies top patent professionals in key jurisdictions around the globe. Additionally, the…
- IAM Strategy 300 Names Partner Danny Huntington One of World’s Leading IP Strategists
Rothwell Figg partner R. Danny Huntington has been named one of the world’s pre-eminent IP strategists in the 2017 edition of IAM Strategy 300 – The World’s Leading IP Strategists. The guide identifies individuals leading…
- Obviousness May Soon Return To High Court
Attorneys Derek F. Dahlgren and Spencer J. Johnson were featured in IP Law360 for their article entitled "Obviousness May Soon Return to High Court." To read the full article, please visit: https://www.law360.com/articles/935776/obviousness-may-soon-return-to-high-court. …
- Rothwell Figg and Five Attorneys Recognized in Managing Intellectual Property's IP Stars 2017 Rankings
Rothwell Figg is pleased to announce that the firm and five attorneys have been recognized in the IP Stars 2017 rankings by Managing Intellectual Property (MIP). As a well-respected publisher in the IP industry, MIP’s…
- Alternative Dispute Resolution
- Biologics and Biosimilars
- Biology and Biotechnology
- Electrical and Computer
- Food and Drug Administration Practice
- Hatch-Waxman Litigation
- International Trade Commission
- Licensing and Transactions
- Media and Financial Services
- Patent Prosecution
- Post-Grant Trial Practice
- Software, E-Commerce and Business Methods
- Trademark Trial and Appeal Board
- Unfair Competition